This time, Aagami has a new client from South Korea. The recent trips to the country has been fruitful. Apart from this new assignment, more are in di...
Published : 02 Jun 2017
Read MoreAnother day, Another assignment for Aaagami. Client is a high growth US MedTech, advancing the next generation of affordable, portable, minimally inva...
Published : 15 May 2017
Read MoreAagami has received a new assignment from a new client for strategic advisory and partnership development.Client is a bio-targeted nanomedicines ...
Published : 06 May 2017
Read MoreAagami announces a new client win. Aagami has received a mandate for strategic advisory and cross border licensing partnering.The UK based clien...
Published : 15 Apr 2017
Read MoreIn keeping up with the annual tradition, Aagami is participating in JP Morgan Healthcare conference and BioTech Showcase this January 2017. Both ...
Published : 09 Nov 2016
Read MoreAagami has been appointed for BD support, by an independent global Contract Research Organization (CRO) offering comprehensive non clinical GLP r...
Published : 01 Nov 2016
Read MoreA UK based pharma company has appointed Aagami to look for strategic partnership relating to their branded generics laxative for treatment of chronic ...
Published : 01 Nov 2016
Read MoreA US biotechnology-based pharmaceutical company focused on the development and commercialization of novel cancer therapies has appointed Aagami to see...
Published : 21 Oct 2016
Read MoreAagami CEO Dinesh Jain will visit Seoul in South Korea in December 2016, to attend the Korea Drug Development Fund Techfair 2016. He is a key speaker ...
Published : 21 Oct 2016
Read MoreA Canada based past client of Aagami, has appointed Aagami for seeking licensing/do-development partnerships for their Phase 3 chemotherapy candidate,...
Published : 23 Sep 2016
Read More